ESOMEPRAZOLE 20MG AND 40MG FOR 26 WEEKS REDUCES THE FREQUENCY OF UPPER GASTROINTESTINAL SYMPTOMS IN PATIENTS TAKING LOW-DOSE ACETYLSALICYLIC ACID FOR CARDIOVASCULAR PREVENTION: THE OBERON TRIAL

(1) UNIVERSITY OF MICHIGANHOSPITALS, Ann Arbor, UnitedStates

(2) Department of Molecular and Clinical Medicine/Cardiology, Sahlgrenska University Hospital, G

(3) Medicine, Oslo UniversityHospital, Oslo, Norway

(4) Medicine, University ofZaragoza, Zaragoza, Spain

(5) University of Alberta, Edmonton, Canada

(6) Statistics and Informatics, AstraZeneca R&D, Mölndal, Sweden

(7) AstraZeneca R&D, Mölndal, Sweden



This item was part of the Oesophageal, Gastric and Duodenal Disorders III session at UEG Week Barcelona 2010

This item can be cited as: Gut 2010; 59 (Suppl III) A342